<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05066867</url>
  </required_header>
  <id_info>
    <org_study_id>CorkUMH</org_study_id>
    <nct_id>NCT05066867</nct_id>
  </id_info>
  <brief_title>LMWH Compliance in Pregnancy</brief_title>
  <official_title>Compliance With Long-term Low-molecular-weight Heparin Prophylaxis/Treatment in the Anatenatal and Postnatal Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cork University Maternity Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HealthBeacon ICMS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cork University Maternity Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective chart study that will aim to assess objective data on compliance levels&#xD;
      to low molecular weight heparin (LMWH) injections among pregnant and postnatal women&#xD;
      undergoing VTE thromboprophylaxis treatment at Cork University Maternity Hospital. This is a&#xD;
      study that will help shine light on accurate data for compliance and possible factors&#xD;
      affecting it, which will be useful for more individualised treatment plans for future&#xD;
      patients. Patients at higher risk of Venous thromboembolism undergoing VTE thromboprophylaxis&#xD;
      will be invited to participate in the study. Once the patient reads the information leaflet&#xD;
      and signs consent, data will then be collected from the patients medical record. The patient&#xD;
      will be given a smart sharps bin with an individual, unique product code. This device will be&#xD;
      provided by HealthBeacon, a Dublin based start-up company. The device will be personalised&#xD;
      with the treatment schedule pre-loaded onto it. When a used LMWH injection is disposed into&#xD;
      the smart sharps bin, an infrared sensor is activated. The system captures an image of the&#xD;
      injection in the chamber before moving it to the normal 'sharps' container of the bin for&#xD;
      disposal. The captured image is time-stamped and sent to HealthBeacon's electronic database.&#xD;
      HealthBeacon will only have the data pertaining to the disposal of injections for each sharps&#xD;
      bin (i.e. the timing of the disposal of each used injection in each pre-coded bin). We are&#xD;
      blinded to the compliance information and will only will receive the raw Data once treatment&#xD;
      is completed. Data will be analysed to determine compliance of LMWH injections. This study&#xD;
      will enable us to have a better insight on accurate compliance rates for LMWH injections in&#xD;
      pregnant women at higher risk for venous thromboembolism (VTE). Understanding compliance with&#xD;
      LMWH injections and the factors which can affect it, will hopefully guide future information&#xD;
      and education that we offer to patients who are prescribed LMWH injections and help decrease&#xD;
      maternal mortality rates in future.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>LMWH compliance levels in pregnancy</measure>
    <time_frame>18 months</time_frame>
    <description>Compliance is described as a patient taking at least 80% of LMWH injections</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sociodemographic factors</measure>
    <time_frame>18 months</time_frame>
    <description>To determine sociodemographic factors that influence compliance</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Antenatal Deep Vein Thrombosis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Smart sharps bin - collects data on compliance</intervention_name>
    <description>collects compliance data</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Antenatal and postnatal women at higher risk of VTE, commenced on LMWH &amp; fitting the&#xD;
        inclusion criteria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  current VTE&#xD;
&#xD;
          -  previous history of VTE&#xD;
&#xD;
          -  class III obesity&#xD;
&#xD;
          -  history of placenta mediated complications&#xD;
&#xD;
          -  pre-eclampsia&#xD;
&#xD;
          -  Advanced Maternal Age&#xD;
&#xD;
          -  inherited thrombophilia&#xD;
&#xD;
          -  prolonged immobilization&#xD;
&#xD;
          -  varicose veins&#xD;
&#xD;
          -  other risk factors that predispose them to VTE&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  life-long anti-coagulation&#xD;
&#xD;
          -  mechanical heart valves&#xD;
&#xD;
          -  other forms of injectable therapy for other illnesses&#xD;
&#xD;
          -  long-term severe physical disability affecting mobility (eg: paraplegia, paralysis&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Antenatal and postnatal woman at higher risk of VTE commenced on LMWH thromboprophylaxis fitting the inclusion criteria</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John RJ Higgins, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CUMH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rebecca M Cole, M.B.</last_name>
    <phone>+353214920500</phone>
    <email>rebecca.cole@ucc.ie</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>John RJ Higgins, M.D.</last_name>
    <phone>+353214920749</phone>
    <email>j.higgins@ucc.ie</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cork University Maternity Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Cole</last_name>
      <email>rebecca.cole@ucc.ie</email>
    </contact>
    <investigator>
      <last_name>Rebecca Cole</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fergus McCarthy</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karthika Annamalai</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ali Khashan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>September 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cork University Maternity Hospital</investigator_affiliation>
    <investigator_full_name>John R Higgins</investigator_full_name>
    <investigator_title>Professor/Clinical Director</investigator_title>
  </responsible_party>
  <keyword>Pregnancy thromboprophylaxis</keyword>
  <keyword>LMWH compliance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

